Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma

References

• Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.
   Google Scholar
• Pizzolo G, Romagnani S. CD30 molecule (Ki-1 Ag): more than just a marker of CD30 + lymphoma. Haematologica 1995;80:357–366.
   PubMed Web of Science ®Google Scholar
• de Claro RA, McGinn K, Kwitkowski V, et al. U.S.Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012;18:5845–5849.
   PubMed Web of Science ®Google Scholar
• von Tresckow B, Engert A. Refractory Hodgkin lymphoma. Curr Opin Oncol 2013;25:463–469.
   PubMed Web of Science ®Google Scholar
• Townsend W, Linch D. Hodgkin's lymphoma in adults. Lancet 2012;380:836–847.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Non-Hodgkin's lymphoma. Version 1.2014. Fort Washington, PA: NCCN; 2014. Available from: www.nccn.org/professionals/physician_gls/f_guidelines_nojava.asp#site
   Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065–2071.
   PubMed Web of Science ®Google Scholar
• Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:589–597.
   PubMed Web of Science ®Google Scholar
• Arden-Close E, Pacey A, Eiser C. Health-related quality of life in survivors of lymphoma:a systematic review and methodological critique. Leuk Lymphoma 2010;51:628–640.
   PubMed Web of Science ®Google Scholar
• Tolley K. What are health utilities?Available from: www.medicine.ox.ac.uk/bandolier/painres/download/whatis/Health-util.pdf
   Google Scholar
• The EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.
   PubMed Web of Science ®Google Scholar
• Bloom JR, Fobair P, Gritz E, et al. Psychosocial outcomes of cancer:a comparative analysis of Hodgkin's disease and testicular cancer. J Clin Oncol 1993;11:979–988.
   PubMed Web of Science ®Google Scholar
• Hjermstad MJ, Fosså SD, Oldervoll L, et al. Fatigue in long-term Hodgkin's disease survivors: a follow-up study. J Clin Oncol 2005;23:6587–6595.
   PubMed Web of Science ®Google Scholar
• Joly F, Henry-Amar M, Arveux P, et al. Late psychosocial sequale in Hodgkin's disease survivors: a French population-based case-control study. J Clin Oncol 1996:14:2444–2453.
   PubMed Web of Science ®Google Scholar
• Rüffer JU, Flechtner H, Tralls P, et al. Fatigue in long-term survivors of Hodgkin's Lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer 2003;39: 2179–2186.
   PubMed Web of Science ®Google Scholar
• Borchmann P; GHSG. Quality of life in Hodgkin's lymphoma patients with special emphasis on fatigue. Presented at: 8th International Symposium on Hodgkin's Lymphoma, Cologne, Germany, 25 October 2010.
   Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Office of National Statistics (ONS). 2011 Census data. Available from: www.ons.gov.uk/ons/guide-method/census/2011/index.html
   Google Scholar
• IBGE (Brazilian Institute of Geography and Statistics) for Brazil, census 2010. Available from: www.ibge.gov.br/english/estatistica/populacao/censo2010/
   Google Scholar
• Instituto nacional de Estadistica y Geografia for Mexico, 2010. Available from: www.ons.gov.uk/ons/guide-method/census/2011/index.html
   Google Scholar
• Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5:1–30.
   PubMed Web of Science ®Google Scholar
• Lloyd AJ, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer 2006;95:683–690.
   PubMed Web of Science ®Google Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008;6:84.
   PubMed Web of Science ®Google Scholar
• Xiao-dong M, Lan-ping X, Dai-hong L, et al. Health related quality of life among patients with chronic graft-versus host disease in China. Chin Med J 2013;126:3048–3052.
   PubMed Web of Science ®Google Scholar
• Ortegon M, Redekop W, Niessen L. Cost-effectiveness of prevention and treatment of the diabetic foot. A Markov analysis. Diabetes Care 2004;27:901–907.
   Google Scholar
• Beusterien K, Davies J, Leach M. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes 2010;8:50.
   PubMed Web of Science ®Google Scholar
• Dolan P, Gudex C, Kind P. The time trade-off method: results from a general population study. Health Econ 1996;5:141–154.
   PubMed Web of Science ®Google Scholar
• Gupta V, Srinivasan G, Mei S et al. Utility values among glaucoma patients: an impact on the quality of life. Br J Ophthalmol 2005;89:1241–1244.
   PubMed Web of Science ®Google Scholar
• Stafford M, Hareendran A, Ng-Mak D, et al. EQ-5D™-derived utility values for different levels of migraine severity from a UK sample of migraineurs. Health Qual Life Outcomes 2012;10:65.
   PubMed Web of Science ®Google Scholar
• Sakthong P, Charoenvisuthiwongs R, Shabunthom R. A comparison of EQ-5D index scores using the UK, US, and Japan preference weights in a Thai sample with type 2 diabetes. Health Qual Life Outcomes 2008;6:71.
   PubMed Web of Science ®Google Scholar
• Tongsiri S. The Thai population based preference scores for EQ5D health states. Bangkok: Ministry of Public Health; August 2009.
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London, UK: NICE; June 2008. Available from: www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf
   Google Scholar